Who invested in Allogene Therapeutics

2 rounds we have observed, with the 3 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Raised 7 months ago

Funding summaryUpdated 26 Oct 2026

$310Mraised across 2 rounds since 2024, from 2 sources

$110MRound$200MRound

Latest round: Round, $200MApr 2026
Step-upi: 1.8×
Investors: 3

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

20252026

$110MRound$200MRound

First round: Round, $110M
Biggest round: $200M
Between rounds: 23 months

The rounds

Apr 2026
Round$200M3 returning
Source recorded
May 2024
Round$110M3 new
Source recorded

Founders and team

From Allogene Therapeutics's own website and the SEC filings it signed: 5 on the team.

Susie LundeenChief People Officer
Earl DouglasGeneral Counsel
In MemoriamDavid Bonderman, Lead Independant Director of Allogene
David M. TanenExecutive Officeri
Joshua A. KazamExecutive Officer, Directori

On the board, as filediArie M. BelldegrunDavid M. BondermanDavid M. ChangFranz M. HumerOwen M. WitteRobert M. AbrahamTodd M. Sisitsky

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Round2024Round2026

Perceptive Advisors

TPG

Franklin Templeton

Everyone who backed them

Perceptive AdvisorsAsset manager2rounds

TPGPrivate equity2rounds

Franklin TempletonPrivate equity2rounds

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists Allogene Therapeutics as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.